The rate and extent of accumulation of clobazam and its major metabolite, desmethylclobazam, during multiple dosage with clobazam were evaluated in 4 similarly sized groups of young male, young female, elderly male, and elderly female volunteers. Subjects received single 10mg doses of clobazam daily for 22 consecutive days. Plasma levels were measured during and after the period of dosage. Compared with the young male subjects, elderly males had slower rates of clobazam accumulation and washout, higher steady-state plasma levels, and lower steady-state clearance. Accumulation of desmethylclobazam also was slower and more extensive in the elderly male group. Among females, however, age-related kinetic differences did not approach significance.
Among all subjects, pharmacokinetic variables for clobazam determined in a previous single-dose study were highly consistent with the multiple-dose pharmacokinetic profile. Singledose vs post-multiple dosage half-life, single-dose vs steady-state clearance, observed vs predicted accumulation ratios, and observed vs predicted steady-state plasma concentrations were all highly correlated, with regression line slopes close to unity. Thus, reduced singledose clearance of clobazam in elderly men leads to slower and more extensive accumulation during multiple dosage. The single-dose pharmacokinetic profile of clobazam is highly predictive of drug behaviour during repeated dosage, suggesting that clobazam kinetics are dose- and concentration-independent within the range studied, and that self-induction or inhibition of clearance is not evident during 3 weeks of dosage.
Clobazam Accumulation Ratio Desmethyldiazepam Regression Line Slope Young Male Subject
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs 20: 161–178 (1980).PubMedCrossRefGoogle Scholar
Greenblatt, D.J.: Electron-capture GLC determination of clobazam and desmethylclobazam in plasma. Journal of Pharmaceutical Sciences 69: 1351–1352 (1980).PubMedCrossRefGoogle Scholar
Greenblatt, D.J.; Allen, M.D.; Harmatz, J.S. and Shader, R.I.: Diazepam disposition determinants. Clinical Pharmacology and Therapeutics 27: 301–312 (1980).PubMedCrossRefGoogle Scholar
Greenblatt, D.J.; Allen, M.D.; MacLaughlin, D.S.; Huffman, D.H.; Harmatz, J.S. and Shader, R.I.: Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. Journal of Pharmacokinetics and Biopharmaceutics 7: 159–179 (1979).PubMedGoogle Scholar
Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.; Harmatz, J.S. and Shader, R.I.: Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. Journal of Pharmacology and Experimental Therapeutics 220: 120–126 (1982a).PubMedGoogle Scholar
Greenblatt, D.J.; Divoll, M.; Harmatz, J.S.; MacLaughlin, D.S. and Shader, R.I.: Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clinical Pharmacology and Therapeutics 30: 475–486 (1981b).PubMedCrossRefGoogle Scholar
Greenblatt, D.J.; Divoll, M.; Puri, S.K.; Ho, I.; Zinny, M.A. and Shader, R.I.: Clobazam kinetics in the elderly. British Journal of Clinical Pharmacology 12: 631–636 (1981a).PubMedCrossRefGoogle Scholar
Greenblatt. D.J. and Koch-Weser, J.: Clinical pharmacokinetics. New England Journal of Medicine 293: 702–705 and 964-970 (1975).PubMedCrossRefGoogle Scholar
Greenblatt, D.J.; Sellers, E.M. and Shader, R.I.: Drug disposition in old age. New England Journal of Medicine 306: 1081–1088 (1982b).PubMedCrossRefGoogle Scholar
Greenblatt, D.J. and Shader, R.I.: Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metabolism Reviews 8: 13–28 (1978).PubMedCrossRefGoogle Scholar
Hanks, G.W.; Lader, M.H. and Lawson, D.H. (Eds): Proceedings of a Symposium on Clobazam. British Journal of Clinical Pharmacology 7 (Suppl. 1): 1S–I55S (1979).Google Scholar
Hindmarch, I.; Lal, H. and Stonier, P.D. (Eds): Pharmacology of clobazam. Drug Development Research (Suppl. 1): 1–184 (1982).Google Scholar
Ochs, H.R.; Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.; Feyerabend, H. and Dengler, H.J.: Diazepam kinetics in relation to age and sex. Pharmacology 23: 24–30 (1981).PubMedCrossRefGoogle Scholar
Reidenberg, M.M.; Levy, M.; Warner, H.; Coutinho, C.B.; Schwartz, M.A.; Yu, G. and Cheripko, J.: Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clinical Pharmacology and Therapeutics 23: 371–374 (1978).PubMedGoogle Scholar
Shader, R.I.; Greenblatt, D.J.; Ciraulo, D.A.; Divoll, M.; Harmatz, J.S. and Georgotas, A.: Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology 75: 193–197 (1981).PubMedCrossRefGoogle Scholar